Joseph D Tariman1, Ardith Doorenbos2, Karen G Schepp3, Pamela S Becker4, Donna L Berry5. 1. College of Science & Health, De Paul University, USA. 2. Biobehavioral Nursing & Health Systems Department, University of Washington, USA. 3. Psychosocial & Community Health Department, University of Washington, USA. 4. Division of Hematology, University of Washington and Seattle Cancer Care Alliance, USA. 5. Dana Farber Cancer Institute, Harvard Medical School, USA.
Abstract
AIMS: To examine patient perspectives on their personal and contextual factors relevant to TDM. The second aim was to describe physician perspectives on the TDM in older adults (≥60 y.o.) diagnosed with symptomatic MM. STUDY DESIGN: Descriptive, cross-sectional. METHODOLOGY: A semi-structured interview schedule was administered. Directed content analysis procedures were used to develop major themes from the patient and physician participant interviews. RESULTS: Themes related to treatment decision making among patient participants include various decisional role preferences; several sources of information related to myeloma; contextual and patient-specific factors influence treatment decisions; negative perceptions related to the treatment decision-making process exist; strong desire to be in remission and to live a longer life; For physician participants, top themes related to decision making were: QOL or survival considerations or simultaneously considerations of treatment effectiveness, QOL and survival; screening patients for eligibility for autologous HSCT; time is a barrier to effective TDM; Various methods were used to assess patient decisional role preferences. CONCLUSIONS: Treatment decision making in older adults newly diagnosed with symptomatic myeloma is influenced by personal, social and contextual factors. Patients must be given the opportunity to choose the best possible treatment within the limits of the patient's personal, social and medical contexts.
AIMS: To examine patient perspectives on their personal and contextual factors relevant to TDM. The second aim was to describe physician perspectives on the TDM in older adults (≥60 y.o.) diagnosed with symptomatic MM. STUDY DESIGN: Descriptive, cross-sectional. METHODOLOGY: A semi-structured interview schedule was administered. Directed content analysis procedures were used to develop major themes from the patient and physician participant interviews. RESULTS: Themes related to treatment decision making among patientparticipants include various decisional role preferences; several sources of information related to myeloma; contextual and patient-specific factors influence treatment decisions; negative perceptions related to the treatment decision-making process exist; strong desire to be in remission and to live a longer life; For physician participants, top themes related to decision making were: QOL or survival considerations or simultaneously considerations of treatment effectiveness, QOL and survival; screening patients for eligibility for autologous HSCT; time is a barrier to effective TDM; Various methods were used to assess patient decisional role preferences. CONCLUSIONS: Treatment decision making in older adults newly diagnosed with symptomatic myeloma is influenced by personal, social and contextual factors. Patients must be given the opportunity to choose the best possible treatment within the limits of the patient's personal, social and medical contexts.
Entities:
Keywords:
Decision making factors; Multiple Myeloma; Older adults; Patient education; Treatment decision making
Authors: Joseph D Tariman; Donna L Berry; Barbara Cochrane; Ardith Doorenbos; Karen G Schepp Journal: Oncol Nurs Forum Date: 2012-01 Impact factor: 2.172
Authors: A K Stewart; P L Bergsagel; P R Greipp; A Dispenzieri; M A Gertz; S R Hayman; S Kumar; M Q Lacy; J A Lust; S J Russell; T E Witzig; S R Zeldenrust; D Dingli; C B Reeder; V Roy; R A Kyle; S V Rajkumar; R Fonseca Journal: Leukemia Date: 2007-01-18 Impact factor: 11.528
Authors: Selwyn O Rogers; Stacy W Gray; Mary Beth Landrum; Carrie N Klabunde; Katherine L Kahn; Robert H Fletcher; Steven Clauser; Diana Tisnado; William Doucette; Nancy L Keating Journal: Ann Surg Oncol Date: 2010-02-17 Impact factor: 5.344
Authors: Kah Poh Loh; Maya Abdallah; Sindhuja Kadambi; Megan Wells; Anita J Kumar; Jason H Mendler; Jane L Liesveld; Marsha Wittink; Kristen O'Dwyer; Michael W Becker; Colin McHugh; Wendy Stock; Navneet S Majhail; Tanya M Wildes; Paul Duberstein; Supriya Gupta Mohile; Heidi D Klepin Journal: Leuk Lymphoma Date: 2020-10-11
Authors: Ellen M H Selten; Johanna E Vriezekolk; Henk J Schers; Marc W Nijhof; Willemijn H van der Laan; Roelien G van der Meulen-Dilling; Rinie Geenen; Cornelia H M van den Ende Journal: BMC Musculoskelet Disord Date: 2017-09-19 Impact factor: 2.362
Authors: Adinda Mieras; Bregje D Onwuteaka-Philipsen; Annemarie Becker-Commissaris; Jose C M Bos; H Roeline W Pasman Journal: BMC Palliat Care Date: 2020-06-19 Impact factor: 3.234
Authors: Ana Isabel Gonzalez; Christine Schmucker; Joerg J Meerpohl; Christiane Muth; Julia Nothacker; Edith Motschall; Truc Sophia Nguyen; Maria-Sophie Brueckle; Jeanet Blom; Marjan van den Akker; Kristian Röttger; Odette Wegwarth; Tammy Hoffmann; Sharon E Straus; Ferdinand M Gerlach Journal: BMJ Open Date: 2019-12-15 Impact factor: 2.692